Therapeutic Response

PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.

Statements

Source and description
Anastrozole Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole as a treatment option for extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.
Arimidex (anastrozole) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive advanced breast cancer.
Arimidex (anastrozole) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer.
Arimidex (anastrozole) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.